Conference Call Details for TG Therapeutics
TG Therapeutics, Inc. (NASDAQ: TGTX) has scheduled a significant conference call on March 3, 2025, at 8:30 AM ET specifically aimed at discussing their financial performance for the fourth quarter and the entirety of 2024. Michael S. Weiss, the Chair and CEO, will lead the discussion.
How to Join the Conference Call
For those interested in joining the call, participants can dial in using the following numbers: 1-877-407-8029 (within the U.S.) or 1-201-689-8029 (for international callers). The conference is titled "TG Therapeutics Earnings Call." Additionally, a live audio webcast will be accessible through the Events page on the company's website.
After the Call – What to Expect
Following the call, attendees will have the opportunity to listen to a recording that will be available for 30 days after the event. This will allow investors and stakeholders to revisit the conference highlights and financial insights shared.
About TG Therapeutics
TG Therapeutics stands firm as a fully integrated biopharmaceutical company dedicated to creating and commercializing innovative therapies for B-cell diseases. The company is known for its robust pipeline of investigational drugs and has successfully gained FDA approval for its product, BRIUMVI (ublituximab-xiiy), aimed at treating adult patients dealing with relapsing forms of multiple sclerosis. This approval is also in line with the European Commission's endorsement and the U.K.'s Medicines and Healthcare Products Regulatory Agency, reinforcing their commitment to delivering novel treatments.
Future Prospects and Innovations
As 2025 approaches, TG Therapeutics is not just reflecting on past achievements but also setting the stage for future endeavors. With ongoing research and development efforts, they aim to expand their portfolio further, focusing on unmet medical needs within the realm of B-cell diseases.
Investment and Growth Strategies
The company's growth strategy is centered around both expanding its existing treatments and exploring new avenues for research. Collaborations with leading healthcare institutions and investment in clinical trials are key components of their plan.
Community and Customer Engagement
Moreover, TG Therapeutics is committed to engaging with the community and stakeholders, emphasizing transparency and communication as vital elements of their operational philosophy. Regular updates on their progress aim to foster trust and reliability among investors and patients alike.
Frequently Asked Questions
What is the purpose of the conference call on March 3, 2025?
The conference call aims to discuss TG Therapeutics' fourth-quarter and full-year financial results for 2024 and outline business expectations for 2025.
Who can participate in the conference call?
Anyone interested in the call can participate by using the specified dial-in numbers provided for U.S. and international callers.
How can I access the recording of the call?
The audio recording will be made available on TG Therapeutics' website for 30 days following the live event.
What medications does TG Therapeutics focus on?
TG Therapeutics specializes in developing treatments for B-cell diseases, particularly noted for its FDA-approved drug BRIUMVI for multiple sclerosis.
How does TG Therapeutics engage with stakeholders?
The company prioritizes transparency and communication with stakeholders through regular updates on research progress and financial outcomes.